

Meeting Agenda



Group: ISPOR 6th Patient Representatives Roundtable – Supported by Pfizer, Roche and Novartis		
Date: Monday, 31 October 2016	Time: 12:30 – 17:00	
Meeting Location: Austria Center Vienna – Vienna, Austria – Room: Hall N (Level 1)		
Time	Topic	Presenter(s)
12:30 - 13:00	Lunch	All Participants
13:00 - 13:10	Welcome and ISPOR Overview	Nadia Naaman
13:10 - 13:45	Introduction of Participants	All Participants
13:45 - 14:00	ISPOR Patient Involvement Activities	Eleanor Perfetto, ISPOR SIG Member
14:00 - 14:10 14:10 - 15:00	<p style="text-align: center;"><u>Role of the Patient in Value Assessments</u></p> <p>Overview Open discussion on:</p> <ul style="list-style-type: none"> • How are Patient Groups providing their perspectives on "value" of new products and technologies to HTA agencies/bodies? • How are HTA agencies/bodies factoring in the patient perspectives? • How to weigh and measure the impact of patient/carer experience in HTA decisions • Whose views should we be listening to during HTA deliberations – those of the affected patient, patient organizations, the tax-paying citizen, or all of the above? 	<p>Moderator: Francois Meyer</p> <p>All Participants</p>
15:00 - 15:15	Coffee Break	All Participants
15:15 - 15:25 15:25 - 16:15	<p style="text-align: center;"><u>Patient Relevant vs Patient Reported Outcomes</u></p> <p>Overview Open discussion on:</p> <ul style="list-style-type: none"> • Patient Relevant Outcomes vs the more traditional, physician driven Patient Reported Outcomes in some disease areas: <ul style="list-style-type: none"> ○ Are their differences meaningful? ○ Is this helping to get patient perspectives to be considered? 	<p>Moderator: Gurmit Sandhu</p> <p>All Participants</p>
16:15 - 16:45	The need for regional and national patient involvement in HTA: The benefits of a joint initiative between EUPATI national platforms and ISPOR Regional Chapters	Jan Geissler
16:45 - 17:00	Next steps and recommendations: Wrap-up and Closing	Nadia Naaman